The study to evaluate the efficacy and safety of using Platelet-rich plasma in treatment of Tear Trough Deformity

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230518002

Enrollment

Registered

2023-05-18

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Platelet-rich plasma, Tear Trough Deformity

Interventions

Patients were treated with platelet rich plasma for 3 session with 1 mont interval and then will be followed up at 2 weeks, 1 month, 2 months, 3 months, and 6 months after the last treatment

Experimental Device

Platelet-rich plasma

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 30-60 years 2. Tear Trough Class I-II by Hirmard's Classification

Exclusion criteria

Exclusion criteria: 1. Pregnancy or Lactation subjects 2. Subjects with coagulopathy or platelet dysfunction or anemia or cancer or immunocompromised host 3. Current smoking or heavy alcohol drinking subjects 4. Subjects with dermatitis, skin infection at eye 5. Subjects with history of anesthesia allergy 6. Subjects with history of taking contraceptive pills or NSAIDs 7. Subjects who treated with energy-based deviced, laser or botox within 6 month before joining the research 8. Subjects who had history of keloid 9. Subjects who had history of phychiatric disease

Design outcomes

Primary

Measure	Time frame
Volume change Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Vectra	—

Secondary

Measure	Time frame
Average Wrinkle and Texture Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Antera,Melanin index Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments mexameter,Erythema Index Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Mexameter,Physician improvement scale Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Percent improvement,Patient improvement scale Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments percent improvement,safety Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments adverse effect	—

Measure

Time frame

Average Wrinkle and Texture Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Antera,Melanin index Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments mexameter,Erythema Index Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Mexameter,Physician improvement scale Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments Percent improvement,Patient improvement scale Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments percent improvement,safety Baseline,1 month after 1st treatment, 1 months after 2nd treatment and 2 week, 1,2,3,6 months after 3rd treatments adverse effect

—

Countries

Thailand

Contacts

Public ContactRungsima Wanitphakdeedecha

Faculty of Medicine Siriraj Hospital, Mahidol University

rungsima.wan@mahidol.ac.th66816406300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026